Monash Partners’
Cancer and Blood Diseases theme, the Monash
Partners Comprehensive Cancer Consortium (MPCCC), will advance collaborative programs outlined in its 2017 – 2021 strategic plan thanks to new funding provided by the Victorian Department of
Health and Human Services (DHHS).
The funding was
confirmed in mid-April and will include $219,000 to pilot a shared care model for cancer related
depression. Aimed at building the capacity of the psych-oncology workforce to
better service the needs of patients across Monash Partners health services, this
pilot program will train and mentor community based psychologists to treat
cancer related depression and will establish a patient referral pathway from
the acute hospital setting to community based services, so that cancer patients
can access these services close to where they live.
“Clinical
depression is the most prevalent psychological condition affecting cancer
patients, but
many patients do not receive treatment for their depression, due to a chronic shortfall in
the hospital based psycho-oncology workforce” said Prof David Kissane, project
lead and Head of the Department of Psychiatry at Monash University, Monash
Health and Cabrini.
“Community
based psychologists aligned with general practices need training to confidently
counsel cancer patients who become depressed, creating a collaborative care
model between psychologist, GP and hospital staff. This is a fantastic
opportunity to improve supportive care services for patients utilising
best-practice integrated models of care. If the model proves effective, we can
use it to help cancer patients suffering with anxiety and adjustment disorders
as well,” said Prof Kissane.
In
addition to funding for MPCCC’s shared care pilot project, DHHS will allocate $500,000
to the MCCC Coordination Unit for governance, planning, program implementation
and funding and communications activities.
“We have worked
closely with the DHHS, Monash Partners and the heads of oncology and research, to
figure out where our collective activity is best focussed to have the biggest
impact for patients” said Prof Gail Risbridger, MCCC Research Director. “This
funding will get us started, but there is still a long road ahead of us”, she
said.
A further proposal to
establish a Precision Oncology program across Monash Partners is also being
considered for funding. This would involve forming a multidisciplinary
Precision Oncology Tumour Board to guide the
selection and sequencing of therapies in patients whose cancer is resistant to
standard treatments.
“There is such great
potential here”, said Prof Eva Segelov, Professor of Oncology at Monash Health and
Monash University and Acting Clinical Director of the Southern Melbourne Integrated
Cancer Service, “It’s just a matter of getting the resources to make it
happen”.
Improving cancer care through better
linkage and sharing of patients’ clinical data remains an important focus of
the MPCCC, with a number of tumour stream based clinical quality registries
currently collecting clinical data through the Monash Department of
Epidemiology. Plans for a pilot program for collecting real-time Patient Reported
Outcomes are also well-developed.
“The DHHS felt these proposals fell
within the remit of the Victorian Agency for Health Information (VAHI) which is
working on the development of a Victorian Clinical Outcome Registry Strategy,
but we are hopeful of working with VAHI to consider a State-wide approach to
these important activities”, said Cancer and Blood Disease Theme representative, Prof John
Zalcberg.
For more information
about MPCCC and its collaborative programs visit: www.monashpartnersccc.org or
contact info@monashpartnersccc.org
No comments:
Post a Comment